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Abstract
Hemangiosarcoma, a natural model of human angiosarcoma, is an aggressive vascular tumor diagnosed commonly
in dogs. The documented expression of several receptor tyrosine kinases (RTKs) by these tumors makes them
attractive targets for therapeutic intervention using tyrosine kinase inhibitors (TKIs). However, we possess limited
knowledge of the effects of TKIs on hemangiosarcoma as well as other soft tissue sarcomas. We report here on the
use of the TKIs imatinib and dasatinib in canine hemangiosarcoma and their effects on platelet-derived growth
factor receptor β (PDGFR-β) and Src inhibition. Both TKIs reduced cell viability, but dasatinib was markedly more
potent in this regard, mediating cytotoxic effects orders of magnitude greater than imatinib. Dasatinib also inhibited
the phosphorylation of the shared PDGFR-β target at a concentration approximately 1000 times less than that
needed by imatinib and effectively blocked Src phosphorylation. Both inhibitors augmented the response to
doxorubicin, suggesting that clinical responses likely will be improved using both drugs in combination; however,
dasatinib was significantly (P < .05) more effective in this context. Despite the higher concentrations needed in
cell-based assays, imatinib significantly inhibited tumor growth (P< .05) in a tumor xenograft model, highlighting
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that disruption of PDGFR-β/PDGF signaling may be important in targeting the angiogenic nature of these tumors.
Treatment of a dog with spontaneously occurring hemangiosarcoma established that clinically achievable doses of
dasatinib may be realized in dogs and provides a means to investigate the effect of TKIs on soft tissue sarcomas in
a large animal model.
Translational Oncology (2013) 6, 158–168
Introduction
Sarcomas consist of a relatively rare and broadly diverse group of
mesenchymal-derived tumors for which there are limited treatment
options. This, along with their infrequent occurrence and clinical and
pathologic diversities, complicates their study, diagnosis, and ultimately
the appropriate treatment strategy. While surgery has been the primary
approach for treating most sarcomas, treatment options have evolved to
include chemotherapy and radiation therapy. Although this approach
has proven effective in extending survival in patients with localized tumors,
many tumors are typically resistant to chemotherapy. Thus, for these
patients and those with metastatic disease, more effective systemic
therapies are greatly needed.
As in most cancers, sarcomas frequently possess abnormalities in
their growth factor signaling pathways with a variety of receptor tyrosine
kinases (RTKs) upregulated or mutated, leading to the activation of the
phosphatidylinositide 3-kinase (PI3K)/Akt or Ras/mitogen-activated
protein kinase (MAPK) pathways. Common activated growth factor
pathways include insulin-like growth factor-1 receptor (IGF-1R) [1–3],
platelet-derived growth factor receptor (PDGFR) [4,5], c-Kit receptor
pathways [6,7], epidermal growth factor receptor (EGFR), and c-Met re-
ceptor pathways [8–10]. In addition to increased RTK expression, fu-
sion genes found in some sarcomas can lead to the overexpression of
normal ligand production, leading to oncogenic signaling [11]. Fur-
thermore, activating mutations such as those found in c-Kit [12–14]
and PDGFR-α [12,15] have been described and shown to be oncogenic
drivers through specific gain-of-function mutations as exemplified by
the Kit gene in gastrointestinal stromal tumors (GISTs). The ubiquity
of dysregulated RTK signaling in sarcomas thus provides a strong ratio-
nale for the development of targeted therapies to inhibit these pathways.
As a result, small molecular tyrosine kinase inhibitors (TKIs), such as
imatinibmesylate and dasatinib, designed to block aberrant signal trans-
duction of implemented kinases, have been explored increasingly and
proven successful for treatment of some sarcoma patients. Imatinib already
plays a role in the treatment of GIST [16,17], and this example currently
defines the paradigm of successful targeted therapy for sarcomas.
While much of the focus in sarcoma tumorigenesis has been and re-
mains on RTKs and their cognitive ligands, potential therapeutic intra-
cellular targets, such as the non-RTK Src, also may prove to be beneficial.
Inhibition of Src and other members of the Src family kinases (SFKs)
have been associated with the inhibition of cell migration and invasion,
and Src represents a point of signaling convergence downstreamofmany
RTKs [18,19]. It has been shown that the transforming capacity of Src
may be linked to its ability to activate key signalingmolecules in RTKpath-
ways rather than through its direct activation. In studieswithEGFR, SFKs
were shown to physically interact with EGFR, and this interactionwas found
to be necessary for full activation of the receptor [20]. Similar occurrences
between SFKs and other RTKs including PDGFRs, fibroblast growth
factor receptor, and IGF-1R have been documented [21]. Thus, treat-
ment of sarcomas with TKIs that disrupt a combination of RTK-Src
interactions may prove to be a more effective strategy.
In dogs, spontaneously arising canine hemangiosarcomas resemble
their human angiosarcoma counterparts in their rapid progression and
metastasis, high mortality, and potential origin from blood vessel–
forming cells [22–24]. However, unlike human angiosarcomas where
the relative incidence is extremely rare, canine hemangiosarcomas occur
abundantly and may represent up to 7% of all canine malignancies
[25]. As a result, examining the effect of TKIs in a strikingly similar
yet more prevalent tumor in dogs may advance treatment options more
rapidly in humans with angiosarcoma or other soft tissue sarcomas.
Here, we demonstrate that inhibition of PDGFR-β phosphoryla-
tion by imatinib or reduced expression by siRNA correlated with the
inhibition of hemangiosarcoma cell viability, indicating the depen-
dence of these cells on PDGFR-β signaling pathways. In addition,
treatment of tumor-bearing mice with imatinib inhibited tumor
growth in a tumor xenograft model. Dasatinib, a TKI known to bind
to and inhibit multiple RTKs including the non-RTK Src, mediated
suppressive effects on canine hemangiosarcoma cell lines several or-
ders of magnitude greater than imatinib and inhibited both PDGFR-β
and Src phosphorylation. Reduced expression of Src by siRNA caused
a decrease in cell viability validating the importance of Src signal-
ing pathways in hemangiosarcoma. Importantly, we found the IC50
of dasatinib to be in the range of clinically achievable concentra-
tions, and this TKI markedly enhanced cytotoxicity of doxorubicin
in hemangiosarcoma cell lines. Our data point to inhibition of specific
tyrosine kinases as a promising strategy for the treatment of this disease
due to the dependence of hemangiosarcomas on signaling through the
PDGFR-β and Src pathways. In addition, the clinical abundance of
hemangiosarcoma and the demonstration of TKI tolerance in dogs
support the application of a large animal model to advance treatment
applications for rare yet similar tumors in humans.
Materials and Methods
Cell Lines and Reagents
The isolation and characterization of two canine hemangiosarcoma
cell lines, SB-HSA and Den-HSA, were described previously by our
group, and were developed from hemangiosarcomas arising from the
subcutis and kidney, respectively [22,26]. OR-HSA is a canine cell line
we developed from a tumor biopsy obtained from the right atrium of a
dog and validated in our laboratory to express von Willebrand’s factor
and αvβ3 integrin, surface proteins highly expressed by canine heman-
giosarcoma [22,23]. The EF-HSA (Emma) cell line was provided by
Dr Jaime Modiano [27]. Cells were grown as adherent cultures in
endothelial growth medium, EBM medium (Lonza, Walkersville,
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MD), enriched with the EGM-2 Bulletkit (Lonza) containing 2% FBS
and the growth factors vascular endothelial growth factor (VEGF), basic
fibroblast growth factor, EGF, and IGF-1. In experiments requiring
serum-starved cells, cells were cultured in EBM medium without the
addition of the Bulletkit. Cells were grown under standard conditions
(37°C, 5% CO2 humidified atmosphere) and were serially passaged
following detachment with 0.25% trypsin plus EDTA. Imatinib was
provided byNovartis (Basel, Switzerland). Dasatinib was obtained from
LC Laboratories (Woburn, MA).
Cell Viability Assays
Cell viability was assessed using the CellTiter 96 Aqueous One
Solution Cell Proliferation (MTS) Assay (Promega, Madison, WI),
as described [28]. Cells suspended in supplemented EGM-2 medium
were seeded in 96-well microtiter plates at a density of 2500 to
10,000 cells per well and allowed to adhere overnight, at which time
various concentrations of the inhibitors were added. Cultures were
maintained for up to 72 hours following addition of inhibitors before
cytotoxic effects were determined. Triplicate cultures of each condi-
tion were evaluated and the mean cell viability for each condition was
used for analysis. All values were compared with controls comprised of
cells cultured under identical conditions without added inhibitors.
Apoptosis Assay
Histone fragmentation was used as a readout of apoptotic cell death.
Nucleosome fragments from SB-HSA cell culture supernatants were
detected using an anti-histone antibody from a commercially available
kit (CellDeathDetectionELISAPlus; Roche, Indianapolis, IN).The assay
was carried out using a colorimetricmicroplate format. All conditions were
examined in triplicate. Cells were also observed undergoing apoptosis
using a Nikon Eclipse Ti microscope with attached digital camera.
Inhibition of PDGFR-β and Src Expression by siRNA
Cells (5 × 103 cells/well) were seeded into 96-well plates and allowed
to adhere overnight before transfection with a combination of four
target-specific siRNAs (3 pmol per reaction) against canine PDGFR-β
(Dharmacon, Lafayette, CO), canine Src (Sigma, St Louis, MO), or a
scrambled sequence (Mission siRNA Universal Negative Control #1;
Sigma) using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA)
according to the manufacturer’s directions. After 72 hours, an MTS
assay was used to measure cell viability and was performed as described
above with the exception that quadruplicate cultures of each condition
were evaluated. For reverse transcription–polymerase chain reaction
(RT-PCR), cells (2 × 106 cells/well) were seeded into six-well plates and
allowed to adhere overnight. Cells were transfected with siRNA (90 pmol
per reaction) using RNAiMAX according to the manufacturer’s instruc-
tions. RNA was isolated from cells at the indicated time points using an
RNeasy Kit (Qiagen, Valencia, CA), and cDNA was synthesized using a
SuperScript VILO cDNA Synthesis Kit (Invitrogen). PDGFR-β and Src
were amplified from the cDNA using canine-specific PDGFR-β and Src
forward and reverse intron spanning primers (BioMedical Genomics
Center, University ofMinnesota). PCRwas performed for 30 cycles using
an annealing temperature of 60°C and GoTaq Green Master Mix
(Promega). The sequences of the siRNAs (5′–3′) are given as follows:
PDGFR-β
Sequence #1: CCUUCAAGGUGGUGGUGAUTT
Sequence #2: CCAUGAACGAACAGUUCUATT
Sequence #3: GAAAUGAGGUGGUUAACUUTT
Sequence #4: GAAUGACCAUCGAGAUGAATT
Src
Sequence #1: UGACGGAGCUCACGACAAA
Sequence #2: GGACAUGGCCGCUCAGAUC
Sequence #3: GCACGGGACAGACAGGCUA
Sequence #4: CGGAUUUCGACAACGCCAA
The sequences for the PCR primers (5′–3′) are given as follows:
PDGFR-β PCR primers:
Forward: CGAGGGTGACAACGACTACA
Reverse: TCTGGTTCTGGCTCCTCTTG
Src PCR primers:
Forward: CAAGATCACCAGACGGGAGT
Reverse: CAGGCTGTTGAACTGTGTGC
Immunohistochemistry
Archived formalin-fixed, paraffin-embedded canine hemangio-
sarcoma biopsies, obtained from outbred dogs following medically
indicated tumor removal surgery, were examined for membrane expres-
sion of c-Kit, PDGFR-β, and VEGF receptor 2 (VEGFR-2) using
immunohistochemical methods. Primary antibodies consisted of anti–
c-Kit (CD117, Cell Marque, Rocklin, CA; 1:50), anti–PDGFR-β (Santa
Cruz Biotechnology, Santa Cruz, CA; 1:100), and anti–VEGFR-2 (Santa
Cruz Biotechnology; 1:200). These antibodies were validated for the dog
using cytologic and fresh frozen samples obtained from SB-HSA tumors
established in mice [22] and formalin-fixed, paraffin-embedded cultured
canine SB-HSA cells as well by immunoblot analysis following antigen
retrieval. Isotype-matched antibodies were used as controls for nonspecific
binding. The final product was developed using alkaline phosphatase with
New Fuchsin as the chromogen (Histo-Mark Red kit; Kirkegaard and
Perry Laboratories, Gaithersburg, MD), as described [22]. Red colora-
tion was considered positive staining indicative of membrane expression
of c-Kit, PDGFR-β, and VEGFR-2, respectively. Immunohistochemistry
was performed by IHC Services (Smithville, TX).
Immunoblot Analyses
Cells were grown to confluency in 10-cm dishes in EGM-2medium.
For serum starvation, the medium was replaced with serum-free,
supplement-free basal medium (EBM) for 4 hours at 37°C in a humid-
ified 5% CO2 atmosphere. Proteins were extracted using a RIPA buffer
[10 mM Tris, 1% Triton X-100, 0.5% deoxycholate, 0.1% sodium
dodecyl sulfate, 150 mM NaCl, 1× Protease Inhibitor Cocktail for
mammalian cells (Sigma), 2 mM orthovanadate, and 10 mM NaF
(pH 8.0)]. Thirty to 50 μg of cell extracts were resolved on 12%
NuPage Gel in MES (Invitrogen) buffer and transferred to polyvinyli-
dene flouride (PVDF) membranes. The membranes were blocked with
TBS with 0.1%Tween-20 (TBST) and 1.5% bovine albumin followed
by blotting with the appropriate antibodies. All primary antibodies were
diluted in TBST at a 1:1000 dilution: PDGFR-β pY857 (Santa Cruz
Biotechnology), pY99 (Santa Cruz Biotechnology, sc-7020), rabbit
polyclonal anti–PDGFR-β (Santa Cruz Biotechnology, 958), anti-pSrc
rabbit polyclonal antibody against Src pY419 (Abcam, Cambridge,
MA; ab4816), and anti-Src rabbit polyclonal antibody against total
Src (Santa Cruz Biotechnology, sc-18). Secondary antibodies (goat
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anti-mouse or goat anti-rabbit; Santa Cruz Biotechnology) linked to
HRP were diluted 1:20,000 in TBST. Bands were detected using
Supersignal West Pico (Pierce, Rockford, IL) luminal by exposure to
Kodak Biomax Light film.
For immunoprecipitation of PDGFR-β, cells were incubated in 0,
10, or 50 μM imatinib in EGM-2 growth media for 60 minutes and
proteins were extracted in ice-cold buffer contained in the Pierce
Crosslink IP Kit (Pierce) with added phosphatase (Pierce) and pro-
tease inhibitors (Pierce). Extracts were sonicated and cleared by cen-
trifugation and protein concentrations were measured. PDGFR-β was
immunoprecipitated from 0.65 mg protein/sample using a rabbit poly-
clonal antibody (Santa Cruz Biotechnology, sc-432) cross-linked to
agarose beads as directed (Pierce). Proteins were then separated by
electrophoresis and probed using a goat anti–PDGFR-β antibody
(Santa Cruz Biotechnology, sc-1627) for the loading control. The blot
was then stripped with Restore PLUS Western Blot Stripping Buffer
(Pierce) and reprobed with a mouse monoclonal pan-phosphotyrosine
antibody (Santa Cruz Biotechnology, sc-7020) to detect the PDGFR-β
phosphotyrosine signal.
High Throughput Kinase Inhibitor Assay
SB-HSA and OR-HSA cells were plated onto 96-well plates at a
seeding density of 1000 cells per well over graded concentrations of
66 small-molecule kinase inhibitors. Each inhibitor was plated indi-
vidually at four concentrations predicted to bracket the IC50 for that
drug (in particular for dasatinib: 1–1000nM). At the end of the 72-hour
incubation, cell viability was assessed using the CellTiter 96 Aqueous
One Solution Cell Proliferation Assay (Promega). All values were
normalized to the mean of seven wells on each plate containing
no drug. The drug concentration at which growth was inhibited
by 50% (IC50) for each drug was then determined by identification
of the two concentrations bracketing the 50% cell viability value as
described [29].
Sequencing of PDGFR-β and 3′ Rapid
Amplification of cDNA Ends
The PDGFR-β sequence in several hemangiosarcoma cell lines was
analyzed for potential truncations and point mutations. For SB-HSA,
nested primers were used in conjunction with PCR to sequence the
cDNA by walking the full length (approximately 3000 bp) of the
PDGFR-β sequence. Several commercial kits were used for this work
including Qiagen Qiaex II DNA, FideliTaq PCR Master Mix (high
fidelity), and Invitrogen Superscript III for cDNA prep and Taq
Polymerase for PCR, and PCR products were sequenced at the Oregon
State University Center for Genome Research and Biocomputing
Core Laboratories.
To determine the sequence of the 3′ end of PDGFR-β, 3′ Rapid
Amplification of cDNA Ends (3′RACE) was performed using the 3′
RACE System (Invitrogen). RNA was isolated from SB-HSA cells
using TRIzol Reagent (Invitrogen) followed by first-strand cDNA
synthesis using the Adapter Primer provided in the 3′RACE System
Kit and following the manufacturer’s instructions. Nested 3′RACE
was performed using the following primers for canine PDGFR-β:
Primer 1: 5′-ACCGCACGCTAGGCGACTCCA-3′
Primer 2: 5′-AGCGGGGAGCAGACAGTCCGA-3′
Primer 3: 5′-TTGGGCAGGTGGTGGAGGCGA-3′
The resulting bands were cloned into anA-T cloning vector (Invitrogen)
and transfected into One Shot Top10 chemically competent bacterial
Figure 1. Imatinib inhibits cell viability by inducing apoptosis of canine hemangiosarcoma cells. (A) Imatinib was added in increasing
concentrations to three canine hemangiosarcoma cell lines (SB, DEN, OR), and the viability of the cells was assessed after 72 hours. IC50
values of 50, 79, and 65 μM were determined for the SB, DEN, and OR cell lines, respectively. The data shown are representative of a
minimum of two independent experiments and all samples were tested in triplicate. (B) Histone fragmentation was used as a readout of
apoptosis to verify the effect of imatinib on the SB-HSA line. The data shown are representative of two experiments, each performed in
triplicate. (C) Time course photomicroscopy was used to observe apoptotic body formation of SB-HSA cells after treatment with im-
atinib. Cultures of SB-HSA cells are shown without imatinib treatment. (D) Apoptotic bodies (arrows) are visible after 4 hours of exposure
to imatinib. (E) After 16 hours, cells exhibited profound morphologic deterioration (arrows).
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cells (Invitrogen). Plasmids were isolated using the Plasmid Midi Kit
(Qiagen), and the purified plasmid was sent to the Biomedical Genomic
Center at the University of Minnesota for sequencing.
Mice
Non-obese diabetic severe combined immunodeficiency (NOD-SCID)
mice were purchased from Jackson Laboratories (Bar Harbor, ME). Ani-
mals were bred and housed in an American Association for the Accredita-
tion of Laboratory Animal Care–approved facility, and all experiments
were conducted with the approval of the Research Animal Resources
Committee of the School of Veterinary Medicine, University of
Wisconsin (Madison, WI). All mice were 8 to 12 weeks old at the ini-
tiation of the described studies.
Xenograft Tumor Model
NOD-SCID mice were injected subcutaneously over the dorsum
with 5 × 106 SB-HSA cells in 200 μl of phosphate-buffered saline
(PBS), as described [22]. Mice were examined daily for tumor devel-
opment. Once tumors were palpable, mice were placed randomly
into groups to receive placebo (PBS) or two different doses of ima-
tinib (25 or 50 mg/kg). Imatinib was administered once daily, intra-
peritoneally for four weeks. Two perpendicular diameters were measured
with calipers and tumor volume was calculated using the formula (D)
(d2)π/6, with D as the largest and d as the smallest diameters. Tumor
growth was plotted as the increase in tumor volume versus time.
Statistical Analysis
Differences between the tumor volumes of the experimental
groups were evaluated using a Kruskal-Wallis test. If significance
was determined (P ≤ .05), then subsequent, pairwise comparisons
(Wilcoxon) were performed to determine the significance between
groups. Differences in MTS assay results were determined using
analysis of variance to compare means of at least three replicate values.
Tukey’s post hoc tests were performed, when appropriate, using
PASW-17 software. The IC50 for each drug was determined by fitting
the relative viability of the cells to the drug concentration by using a
dose-response model in the Prism program from GraphPad Software,
Inc (San Diego, CA). For the siRNA studies, comparisons between
untreated and treated groups were made using a paired Student’s t test.
A probability of 0.05 or less was considered statistically significant.
Results
Imatinib Is a Potent Inhibitor of SB-HSA
Proliferation and Induces Apoptosis
The expression of several tyrosine kinase receptors has been char-
acterized in canine hemangiosarcoma cell lines [22,26], primary tumors,
and their xenograft counterparts [30], indicating that these receptors are
frequently expressed in hemangiosarcoma and, therefore, may represent
therapeutic targets. Using immunohistochemical staining of sections
from archived formalin-fixed, paraffin-embedded tumors, we noted that
PDGFR-β, VEGFR-2, and c-Kit were abundantly expressed (i.e., >50%
of cells staining positive evidenced by membranous red color) in the
majority of the samples (12/13 PDGFR-β, 17/17 VEGFR-2, and
12/13 c-Kit), providing several potential receptor targets for TKIs.
Because of the observed expression of PDGFR-β and c-Kit in pri-
mary hemangiosarcomas, we set out to determine if imatinib, which
targets both receptors, could inhibit the growth of hemangiosarcoma
cell lines. We first examined the effects of imatinib treatment on the
proliferation of three hemangiosarcoma cell lines using a cell viability
assay. Cell viability was inhibited by increasing concentrations of
imatinib, and an IC50 of 50, 79, and 65 μM was determined for each
of the SB-HSA, DEN-HSA, and OR-HSA cell lines, respectively
(Figure 1A).
We next used histone fragmentation as a readout to confirm apop-
tosis as the mechanism for the decreased cell viability. Treatment of
SB-HSA cells with increasing concentrations of imatinib induced
apoptosis in a dose-dependent manner (Figure 1B). The IC50 for this
effect was 11 μM. Visual validation of the apoptotic data was performed
using time course photomicroscopy to compare untreated controls
(Figure 1C ) to those cells treated with imatinib. We observed the
Figure 2. Knockdown of PDGFR-β by siRNA reduces viability of
hemangiosarcoma cells. (A) SB-HSA cells were treated with a canine-
specific siRNA against PDGFR-β. The relative cell viability was
assessed after 72 hours, and cells treated with PDGFR-β siRNA
showed significant inhibition of cell viability when compared to an un-
treated control (*P< .01). Untreated cells were used to determine to-
tal cell viability, and a scrambled siRNA control was used to account
for nonspecific, off-target effects. (B) The siRNAs against PDGFR-β
were validated using RT-PCR to determine the mRNA expression lev-
els of the receptor at 24, 48, and 72 hours after transfection. A scram-
bled siRNA was used as a control for nonspecific siRNA activity.
Figure 3. Imatinib inhibits phosphorylation of PDGFR-β in canine
hemangiosarcoma. SB-HSA cells were treated for 60 minutes with
imatinib, and the total PDGFR-β was immunoprecipitated from cell
lysates. Total PDGFR-β was determined by immunoblot analysis.
The blot was stripped and reprobed with a pan-phosphotyrosine
antibody to determine the levels of phosphorylated PDGFR-β.
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appearance of apoptotic bodies 4 hours after treatment (Figure 1D).
After 16 hours, imatinib-treated cells exhibited profound morphologic
deterioration (Figure 1E ). These results indicate that imatinib is a
potent inducer of apoptosis in canine hemangiosarcoma cells.
PDGFR-β Is Important for Hemangiosarcoma Cell Viability
Because signaling through PDGFR-β has been shown to affect
cellular proliferation and cell survival [31], we investigated the role
PDGFR-β expression in hemangiosarcoma cell viability. Cells trans-
fected with siRNA against canine PDGFR-β showed approximately
45% growth suppression when compared with untreated controls
and after adjusting for nonspecific inhibition of cell viability by a
scrambled siRNA control (Figure 2A). The canine-specific siRNAs
were validated using RT-PCR (Figure 2B). Our results indicate that
PDGFR-β is important for viability of these tumor cells.
Imatinib Inhibits the Phosphorylation of Canine PDGFR-β
We next examined the ability of imatinib to alter the phosphorylation
status of PDGFR-β in hemangiosarcoma. Serum-starved SB-HSA cells
were treated with either 10 or 50 μM imatinib for 60 minutes, and the
effect of imatinib on receptor phosphorylation was determined. Imatinib
blocked tyrosine phosphorylation in a dose-dependentmanner (Figure 3)
with a substantial decrease in phosphorylation occurring at 10 μM and
near-complete inhibition of phosphorylation occurring at 50 μM. After
the effect of imatinib on tyrosine phosphorylation was determined, the
membrane was stripped and reprobed with anti–PDGFR-β to demon-
strate the presence of the receptor for each condition (Figure 3).
Imatinib Inhibits Hemangiosarcoma Tumor Growth in a
Xenograft Model
We next examined the ability of imatinib to inhibit tumor growth
in a subcutaneous tumor xenograft model. Once tumors were palpa-
ble, mice were randomly divided into groups and treated with PBS or
25 mg/kg or 50 mg/kg imatinib by daily intraperitoneal injection.
After four weeks, the size of the tumors in the mice receiving the 50 mg/
kg/day dose was significantly smaller when compared to either the
25 mg/kg/day or placebo group (P = .028; Figure 4). These findings
show that imatinib inhibits hemangiosarcoma tumor growth in a
macroscopic tumor xenograft model and suggest that imatinib or other
TKIs affecting similar targets may be useful for improving the manage-
ment of hemangiosarcoma.
Dasatinib Is a Potent Inhibitor of Hemangiosarcoma
Cell Viability
To explore the potential of other TKIs for inhibitory effects on
hemangiosarcoma cell growth, we screened SB-HSA cells using a
high throughput TKI platform that revealed potent cytotoxic activity
of Src inhibitors (data not shown). In particular, dasatinib, an SFK
inhibitor that also targets PDGFR-β and c-Kit, manifested these ef-
fects in the nanomolar concentration range. When we examined the
cytotoxic effects of dasatinib using the three canine hemangiosarco-
ma cell lines used in the imatinib studies, the IC50 of dasatinib was
110, 69, and 15 nM for the SB-HSA, DEN-HSA, and OR-HSA cell
lines, respectively, indicating that dasatinib may be more effective for
treating hemangiosarcoma than imatinib (Figure 5).
Dasatinib Inhibits PDGFR-β and Src Phosphorylation in
Canine Hemangiosarcoma
Because dasatinib is a potent inhibitor of both PDGFR-β and Src
activation, we examined its ability to suppress the phosphorylation of
these kinases in hemangiosarcoma cell lines. Dasatinib potently inhib-
ited phosphorylation of PDGFR-β (180 kDa) on Y857, a major autop-
hosphorylation site, at both 10 and 100 nM concentrations (Figure 6A).
Thus, the concentration of dasatinib needed to inhibit the phos-
phorylation of PDGFR-β was approximately 1000 times less than that
needed for inducing comparable effects by imatinib (refer to Figure 3).
Figure 4. Imatinib inhibits growth of hemangiosarcoma in a xeno-
graft model. SB-HSA cells were injected subcutaneously over the
dorsum in NOD-SCID mice. When tumor nodules were palpable,
mice were randomized into placebo (PBS) or treatment (25 mg/kg
or 50 mg/kg) groups (n = 6 per group). Imatinib was given once
daily, intraperitoneally for 4 weeks. Tumors were measured weekly
and the tumor volume determined by the formula (D)(d)2(π/6),
where D is the largest tumor diameter and d is the smallest. The
tumor size in mice receiving the higher dose (50 mg/kg) was signif-
icantly different from controls (P = .028) and the 25 mg/kg treat-
ment group by week four. Error bars represent SD. Error bars are
present in the graph for the 50mg/kg data set, but they are obscured
by the symbols used to represent the data set.
Figure 5. Dasatinib inhibits the viability of canine hemangiosar-
coma. The cytotoxic effects of dasatinib were examined on the
three canine hemangiosarcoma cell lines (SB-HSA, DEN-HSA,
and OR-HSA) by using increasing concentrations and determining
the effect on cell viability after 72 hours in culture using the MTS
assay. The IC50 of dasatinib was determined to be 110, 69, and
15 nM for the SB-HSA, DEN-HSA, and OR-HSA cell lines, respec-
tively. The data are representative of a minimum of two indepen-
dent experiments, and each sample was assayed in triplicate.
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Interestingly, we noted that dasatinib also potently inhibited the
phosphorylation of a 120-kDa protein when the Y857 antibody
was used to detect the receptor (Figure 6A). To determine if the
120-kDa protein could be a truncated form of PDGFR-β, we se-
quenced the receptor from the SB-HSA cell line, and we also per-
formed 3′RACE analysis to look for the presence of mutations.
Complete sequencing and 3′RACE analysis revealed that only the
wild-type form of the receptor was present within SB-HSA cells (data
not shown). Thus, the 120-kDa protein might represent an unpro-
cessed form of the receptor, but it does not appear to be specific for
HSA since it is also present in nonmalignant canine fibroblasts (CFs;
Figure W1).
We next examined the effects of dasatinib on Src phosphorylation
using the same dasatinib concentration range shown to inhibit phos-
phorylation of PDGFR-β. We noted partial inhibition of Src phosphor-
ylation at concentrations as low as 1 nM in SB-HSA cells (Figure W2)
with complete inhibition of the kinase at 10 and 100 nM in all three
cell lines (Figure 6B). We next looked downstream in the PDGFR-β/
Src signaling cascade to determine whether proximal blockade by
dasatinib had a domino effect on activated distal signaling molecules
associated with proliferative responses. Extracellular signaling–related
kinases 1 and 2 (ERK1/2) are members of the MAP kinase family that
have been implicated in the downstream signaling pathway of both
PDGFR-β and Src kinase. We examined the phosphorylation status
of ERK1/2 in SB-HSA and DEN-HSA using phosphospecific antibodies.
We observed little to no reduction in phospo-Erk1/2 (pERK1/2) when 1
to 100 nM of dasatinib was used (data not shown). However, a decrease in
pERK1/2 was observed in the SB-HSA and DEN-HSA cell lines when a
higher concentration of dasatinib (10 μM) was used (Figure 6C). While
reduced phosphorylation in SB-HSAwas only partial at this concentration,
the inhibition of phosphorylation in the DEN-HSA cell line was nearly
complete. These results indicate that dasatinib is a potent inhibitor of both
PDGFR-β and Src kinase–mediated cell viability but that these effects may
not be mediated through ERK1/2 kinases in hemangiosarcoma.
Src and PDGFR-β Are Important for
Hemangiosarcoma Cell Viability
While dasatinib has been shown to bind in excess of 30 tyrosine
and serine/threonine kinases [32], Src is a key target for dasatinib and
represents a point of signaling convergence downstream of many
RTKs [18,19]. Because dasatinib showed complete inhibition of Src
phosphorylation at low nanomolar concentrations, we investigated
the role of Src expression on hemangiosarcoma cell viability using
canine-specific siRNAs against the kinase. SB-HSA cells transfected
with Src siRNAs showed approximately 25% growth suppression when
compared with untreated controls and after adjusting for nonspecific
inhibition of cell viability by a scrambled siRNA control (Figure 7A).
Validation of the siRNA targeting using RT-PCR indicated that
expression of Src mRNA was inhibited at all time points examined
(Figure 7B). To determine if inhibition of PDGFR-β and Src kinase
together had an additive or synergistic effect on cell viability, SB-HSA
cells were treated with siRNAs against both kinases. We noted further
inhibition of cell viability in the presence of both siRNA populations
(approximately 45% inhibition), indicating that targeting both kinases
might be of benefit (Figure 7C). However, the observed cell viability
with siRNAs against both targets was similar to that observed for
PDGFR-β alone (Figure 2A), validating the importance of PDGFR-β
signaling in hemangiosarcoma. Taken together, our results support the
conclusion that targeted inhibition of Src kinase, in combination with
inhibition of other RTKs for the treatment of hemangiosarcoma, pro-
vides a more efficacious approach to suppressing growth of this tumor.
Doxorubicin Cytotoxicity Is Potentiated by Dasatinib
Because TKIs in combination with established cancer therapeutic
modalities may be more effective in clinical practice than when used
alone as single-agent therapies, we examined the potential for dasatinib
to act as a chemosensitizer with doxorubicin in hemangiosarcoma.
Doxorubicin is the cornerstone in the clinical management of many
sarcomas including canine hemangiosarcoma. By way of comparison,
we performed parallel experiments with imatinib and various concen-
trations of doxorubicin on the same hemangiosarcoma cell lines.
As 10 nM dasatinib effectively reduced the phosphorylation of
both PDGFR-β and Src in our studies, we used this concentration
to determine if dasatinib could enhance the properties of doxorubicin.
As shown in Figure 8A, dasatinib significantly enhanced the cytotoxic
effects of doxorubicin at all concentrations examined (P < .05). Imati-
nib used at a concentration orders of magnitude greater than the dasa-
tinib (25 μM) appeared to enhance the cytotoxic effects of doxorubicin
Figure 6. Dasatinib is a potent inhibitor of PDGFR-β and Src phos-
phorylation. (A) Increasing doses of dasatinib were incubated with
the cell line SB-HSA and the phosphorylation status of PDGFR-β
determined by immunoblot analysis. PDGFR-β (180 kDa) and a
potentially unprocessed form of the receptor (120 kDa), which is
dephosphorylated by dasatinib, are indicated by arrows. β-Actin
was used as a control to ensure equal loading of samples. (B) Dasa-
tinib was incubated with three different hemangiosarcoma cell lines
(SB-HSA, DEN-HSA, and OR-HSA) for 72 hours, and its effect on
the phosphorylation status of Src in each cell line was determined
by immunoblot analysis of cell lysates using antibodies specific
for the phosphorylated form of the kinase. An antibody against
total Src was used as a control. (C) The effect of dasatinib on ERK
phosphorylation in SB-HSA and DEN-HSA cells was determined
by immunoblot analysis. Cells were incubated with 10 μM dasatinib
for 1 hour and pERK was detected using an antibody specific
for the phosphorylated form of the protein. β-actin was used as a
loading control.
164 Imatinib and Dasatinib Inhibit Hemangiosarcoma Dickerson et al. Translational Oncology Vol. 6, No. 2, 2013
but in a more limited fashion that was not significant when responses of
all three hemangiosarcoma cell lines were considered together (P > .05;
Figure 8B). These results suggest that clinical applications include a
combination of TKI and doxorubicin and that Src blockade mediated
by dasatinib combined with suboptimal concentrations of doxorubicin
provides a highly robust tumoricidal effect against hemangiosarcoma.
Furthermore, the concentration of dasatinib we used in vitro is poten-
tially achievable in vivo in the dog.
Clinical Correlate
In keeping with the translational nature of this study, we had the
opportunity to treat an 11-year-old Golden Retriever dog with dasa-
tinib for hemangiosarcoma as a first step to begin to apply our labo-
ratory findings to a relevant in vivo model. The OR-HSA line used in
these studies (Figures 1A, 5, 6B, and 8) was derived from the dog’s
excised cardiac hemangiosarcoma. The dog presented with stage 3
Figure 7. Knockdown of Src by siRNA reduces viability of heman-
giosarcoma cells. (A) SB-HSA cells were treated with canine-
specific siRNAs against Src, and the relative cell viability was
assessed after 72 hours in culture. Cells treated with Src siRNA
showed significant inhibition of cell viability when compared to an
untreated control (*P< .01). Untreated cells were used to determine
total cell viability, and a scrambled siRNA control was used to
account for nonspecific, off-target effects. (B) The siRNAs against
Srcwere validated using RT-PCR to determine themRNA expression
levels of the kinase at 24, 48, and 72 hours after transfection. A
scrambled siRNA was used as a control. (C) The effect of siRNAs
against PDGFR-β and Src in combination was determined using a
cell viability assay. SB-HSA cells were treated with siRNAs against
both kinases, and the relative cell viability was examined 72 hours
after transfection. Cells treated with siRNAs against PDGFR-β and
Src showed significant inhibition of cell viability when compared to
an untreated control (*P < .01). A scrambled siRNA sequence was
used to assess off-target effects and transfection-related inhibition of
cell viability.
Figure 8. Dasatinib but not imatinib functions as a chemosensitizer
by potentiating cytotoxic effects of doxorubicin in hemangiosar-
coma cell lines. (A) Dasatinib (10 nM) was incubated with increasing
concentrations of doxorubicin, and cell viability was determined
after 72 hours using an MTS assay. Cells treated with dasatinib (▪)
showed increased cytotoxicity in the presence of doxorubicin com-
pared to cells treated with doxorubicin alone (•), and this difference
was significant at all doses examined (P < .05). Data shown are the
combined mean cytotoxicity of three hemangiosarcoma cell lines
(SB-HSA, DEN-HSA, and OR-HSA). (B) SB-HSA, DEN-HSA, and OR-
HSA were incubated with 25 μM of imatinib (▪) and increasing
concentrations of doxorubicin. After 72 hours, the viability of the
cells was examined using an MTS assay and compared to the via-
bility of cells incubated with doxorubicin alone (•). While imatinib
enhanced the sensitivity of doxorubicin in all three cell lines, this
enhancement was not significantly different from cells treated with
doxorubicin alone (P> .05). All values are representative of themean
from three cell lines, and the error bars represent ±1 SD about the
average value.
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cancer affecting its heart, liver, spleen, and lungs and had a life expec-
tancy of less than 1 month. Following cardiac surgery to debulk the
tumor, the dog was started on dasatinib per os and gradually escalated
to a dosage of 1 mg/kg orally given on two to four consecutive days
followed by a rest day. While circulating dasatinib levels were not
determined, plasma levels measured in another dog receiving similar
doses of dasatinib suggest that therapeutic dasatinib concentrations
were likely achieved using this regimen [33]. Antinausea prophylaxis
was provided, and the dog tolerated this regimen well with occasional
periods of reduced appetite that were transient. There were no abnor-
malities detected on routine blood counts and serum biochemical
screens. Doxorubicin was administered concurrently, consistent with
care standards and our in vitro observations of the potential for a com-
bined antitumor effect with dasatinib (Figure 8A). After 3 months,
abdominal hemorrhage secondary to bleeding from hepatic hemangio-
sarcoma metastases required surgical intervention; the dog succumbed
to postoperative complications. Although anecdotal, to our knowledge,
this is the first time a dog with hemangiosarcoma has received dasatinib
and illustrates the feasibility to employ this agent in the dog, strength-
ening the importance of this canine model for evaluating dasatinib
therapy for both human and canine sarcomas.
Discussion
The field of TKIs is expanding rapidly driven by the success of TKIs
as novel anticancer agents, identification of more relevant targets, and
the need to develop more effective drugs for cancer. Imatinib has
revolutionized the treatment of GIST, and this therapy has provided
the first proof of principle that targeted agents such as TKIs can be
effective in the treatment of sarcoma [34]. While few other highly
recurrent driver genes have been described in sarcomas similar to Kit
mutations in GIST, overexpression of a variety of other RTKs or their
ligands appears to play a role in sarcomas. Thus, there is a compelling
rationale to identify and block signaling pathways in sarcoma cells with
TKIs as a next step in the advancement of sarcoma therapy.
Sarcomas can be divided broadly into soft tissue sarcomas and pri-
mary bone sarcomas. These account for approximately 1% of all
adult cancers and 15% of all pediatric cancers [35–37]. The relative
rarity and aggressive character of sarcomas, paired with their highly
refractory nature to conventional therapies, has the potential to hinder
rapid advancement in new treatment modalities. In contrast to humans,
sarcomas are often diagnosed in companion animals [38], and both soft
tissue and bone sarcomas of dogs share striking similarities with their
human counterparts [39–41]. As a result, companion dogs provide a
readily available sample source with clinical relevance to the
corresponding human disease [40]. Canine tumors also can provide a
more rapid assessment of new treatments due to the compressed disease
duration [39]. Thus, spontaneously arising sarcomas in dogs provide a
way to bridge the existing gap in therapeutic development of TKIs for
treatment of human sarcomas.
Like many soft tissue sarcomas, canine hemangiosarcoma is poorly
responsive to conventional therapy and RTK signaling appears ubi-
quitous [22,23,26]. Canine hemangiosarcoma is thought to be a malig-
nancy of vascular forming cells, and tumors are characterized by
structures resembling leaky and highly disorganized neoangiogenic
vessels [22,23,41]. We focused our initial TKI studies on the role of
PDGFR-β/PDGF signaling in these tumors due to the well-documented
role of both PDGFR-β and PDGF in blood vessel formation [42].
Using RNA inhibition to reduce PDGFR-β expression, we noted a
reduction in overall cell viability indicating that signaling through
PDGFR-β is important for hemangiosarcoma cell survival. On the
basis of this result, as well as previous work from our groups indicat-
ing expression of c-Kit by hemangiosarcoma [22,26], and results
from our immunohistochemistry studies demonstrating high expres-
sion of both c-Kit and PDGFR-β, we examined the effects of imati-
nib on several hemangiosarcoma cell lines and in a tumor xenograft
model. While imatinib is most noted for its inhibition of Bcr-Abl in
human chronic myelogenous leukemia, the inhibitor also blocks acti-
vation of and signaling through c-Kit and PDGFR-β [43]. Proliferation
of several hemangiosarcoma cell lines was inhibited by imatinib and
cell viability was further limited when imatinib was used in combina-
tion with doxorubicin though not significantly. Mice bearing canine
hemangiosarcoma xenografts [22] and treated with imatinib had a sig-
nificant reduction in tumor growth. We interpret these results to sup-
port a role for PDGFR-β, and possibly c-Kit, in maintenance and
growth of hemangiosarcomas.
While our studies indicated that imatinib inhibited the viability of
hemangiosarcoma cell lines, the striking inhibition of tumor growth
observed in our mouse model was somewhat surprising. One inter-
pretation of these results is that disruption of PDGFR-β/PDGF sig-
naling may be important in targeting the angiogenic nature of these
tumors due to effects of imatinib on both the tumor cells and the
tumor vasculature. In vascular stroma, PDGFR-β expression occurs
mainly in vascular mural cells (pericytes), while PDGF-BB expression
in certain tumors enhances pericyte recruitment to tumor vessels.
This recruitment results in subsequent tumor vessel stabilization,
survival, and growth [44,45]. In the RIP-Tag mouse model of tumor
angiogenesis, inhibition of PDGFR-β signaling in tumor pericytes
synergized with inhibition of VEGFR signaling in endothelial cells
in suppressing tumor growth [46]. Using a proteomics approach,
our group recently found that approximately 20% of the identified
pathways in canine hemangiosarcoma cell lines contributed to angio-
genesis, motility, or inflammation [47]. These findings were consis-
tent with gene expression profiles identifying inflammatory and
angiogenic mechanisms as distinguishing features of hemangiosarcoma
[41]. Thus, inhibition of PDGFR-β signaling in combination with
other approaches might provide a successful strategy for treatment of
this disease.
Imatinib has been used in dogs and cats primarily to treat mast cell
tumors, and several recent studies have demonstrated responses to
therapy [48]. The effects of imatinib in hemangiosarcoma cells and
impact on tumor growth in vivo unambiguously establish proof of
principle illustrating the potential to arrest hemangiosarcoma cell
proliferation. Although in vitro studies have demonstrated that ima-
tinib inhibits constitutive phosphorylation of c-Kit and growth of
malignant canine mast cells, it requires high concentrations (in the
micromolar range) to demonstrate these activities. Attaining clinically
relevant concentrations in affected animals that could serve as a relevant
large animal model for extending the use of imatinib may be challeng-
ing given that imatinib can induce hepatotoxicity in a proportion of
dogs, and this toxicity resulted in discontinuation of therapy [49].
While the maximum plasma concentration achieved after intravenous
administration falls within the range needed for a clinical effect (10–
30 μM), the plasma concentration in dogs after oral administration is
well below that needed for a response (0.8–2 μM) limiting the potential
of oral drug administration to canine patients [50]. To identify other
TKIs with potential efficacy against hemangiosarcoma and with the
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potential to achieve clinically relevant concentrations through oral
dosing, we employed a high throughput screening platform to exam-
ine the effects of a panel of TKIs on the cell viability of hemangio-
sarcoma cell lines. We noted potent inhibition of hemangiosarcoma
viability in those cells treated with the Src inhibitor dasatinib in the
initial screen.
Dasatinib inhibited in vitro proliferation of canine hemangiosar-
comas several orders of magnitude greater than imatinib, and the
concentration needed to inhibit the phosphorylation of PDGFR-β
was approximately 1000 times less than that needed for inducing
comparable effects by imatinib. Others have noted dasatinib mediated
potent in vitro growth suppression of cultured malignant canine mast
cells [51]. Dasatinib was recently shown to block signaling through
both PDGFR-β and c-Kit [52] and actually targets a larger number
of tyrosine kinases (i.e., SFKs) than imatinib with relatively high affin-
ity. The ability of dasatinib to arrest hemangiosarcoma growth at nano-
molar concentrations may reflect its multitargeting effects. The notable
cooperation between SFK members and EGFR to achieve full activa-
tion of the RTK has been noted in several cancers [53–55], and the
extension of this RTK-Src interaction to other RTKs, including
PDGFRs, has been described [21]. In addition, studies targeting both
the interacting RTK and Src suggest that a combinatorial therapy
directed at both the implicated RTKs and SFKs may be necessary to
overcome acquired resistance to other treatments [56].
Treatment of hemangiosarcoma cell lines, with the Src blocker
dasatinib, showed remarkable sensitivity to the inhibitor that also
potentiated doxorubicin cytotoxicity. Given the abundance of RTKs
expressed by hemangiosarcomas, TKIs that disrupt RTK-Src inter-
actions, specifically PDGFR-β, which appears to be important for
hemangiosarcoma survival, are more effective in suppressing tumor
growth than inhibitors that solely target RTKs. Collectively, our data
suggest a strong rationale for clinical strategies that investigate the use
TKIs directed at both PDGFR-β and SFK in dogs with hemangio-
sarcoma. Such studies should be combined with doxorubicin since clin-
ical response likely will be improved using both treatment approaches.
In summary, we present both a promising treatment strategy for
hemangiosarcoma in dogs as well as a large animal model for clinical
development of TKIs that may have translational potential to human
sarcomas. This approach overcomes one of the main challenges of
developing treatment strategies for sarcomas, that of being relatively
rare in humans, since treatment approaches can be tested more readily
in abundant and spontaneously occurring tumors in companion dogs.
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Figure W1. The relative size of caninePDGFR-β in hemangiosarcoma
cell lines was determined by immunoblot analysis. CFs were used as
a positive control. Phospho–PDGFR-β (180 kDa) was detected in two
(SB-HSA, DEN-HSA) of three hemangiosarcoma cell lines, using an
antibody against PDGFR-β Y857. The 180-kDa protein was not obvi-
ously visible in the EF cell line. A 120-kDa phosphoprotein also was
readily detected in SB-HSA, DEN-HSA, and CFs, but the protein
was expressed in the EF-HSA cell line at much lower levels.
Figure W2. Dasatinib inhibits Src phosphorylation in the SB-HSA
cell line. The inhibition of Src phosphorylation was examined after
treatment of SB-HSA cells with increasing concentrations of dasa-
tinib. Dasatinib partially inhibited Src at concentrations as low as
1 nM, and complete inhibition was observed at both the 10 and
100 nM concentrations.
